Topamax

How to order Topamax

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Topamax on Prescriptsy

Topamax is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Topamax is the brand name for topiramate, an anti-epileptic drug (AED) licensed in the United Kingdom for the treatment of epilepsy and the prophylaxis (prevention) of migraine headaches.

Topiramate has multiple mechanisms of action that distinguish it from other anti-epileptic drugs, giving it a broad spectrum of anti-seizure activity.

It is approved for use as monotherapy and adjunctive therapy in adults and children with various seizure types, and for migraine prevention in adults.

Topamax is manufactured by Janssen and is also available as generic topiramate from multiple UK suppliers.

Epilepsy affects approximately 600,000 people in the United Kingdom, making it one of the most common neurological conditions.

Migraine affects an estimated 10 million people in the UK and is a leading cause of disability globally.

Effective pharmacological management of both conditions can significantly improve quality of life, reduce disability, and prevent serious complications.

This page provides comprehensive clinical information about Topamax, including how topiramate works, dosing guidance, the full range of potential side effects, essential safety warnings including the MHRA Pregnancy Prevention Programme, and how to obtain a prescription in the UK.

Important safety information about Topamax

Before reading further, note the following critical safety points about Topamax.

• Topiramate is a known teratogen. It must not be used during pregnancy unless there is no suitable alternative and the conditions of the MHRA Pregnancy Prevention Programme are met. It is associated with cleft lip, cleft palate, and fetal growth restriction.
• Women and girls of childbearing potential must use effective contraception throughout treatment. Note that topiramate may reduce the effectiveness of hormonal contraceptives at doses above 200 mg per day.
• Do not stop Topamax suddenly if you have epilepsy. Abrupt withdrawal can trigger rebound seizures.
• Drink plenty of water (at least 2 litres per day) to reduce the risk of kidney stones.
• Report any changes in mood, behaviour, or suicidal thoughts to your prescriber immediately.

What is epilepsy

Epilepsy is a neurological disorder characterised by a predisposition to recurrent unprovoked seizures. Seizures result from abnormal, excessive, or synchronous neuronal activity in the brain.

The clinical manifestation of a seizure depends on the location and extent of the abnormal activity.

Focal (partial-onset) seizures originate in a specific brain region and may remain localised or spread to become bilateral tonic-clonic seizures.

Generalised seizures involve both cerebral hemispheres from onset and include tonic-clonic (grand mal), absence (petit mal), myoclonic, tonic, and atonic seizures.

Lennox-Gastaut syndrome is a severe childhood-onset epilepsy syndrome characterised by multiple seizure types, cognitive impairment, and a characteristic slow spike-wave pattern on EEG.

Epilepsy in the UK

The Epilepsy Society estimates that approximately 1 in 100 people in the UK have epilepsy. Around 87 people are diagnosed every day.

The condition can begin at any age but is most commonly diagnosed in childhood or after the age of 65.

NICE Guideline NG217 (Epilepsies in children, young people and adults) provides comprehensive recommendations for the diagnosis, investigation, and management of epilepsy in the UK.

Anti-epileptic drugs are the mainstay of treatment, with the choice of drug determined by seizure type, epilepsy syndrome, patient age, sex, childbearing potential, comorbidities, and tolerability.

What is migraine

Migraine is a primary headache disorder characterised by recurrent attacks of moderate to severe pulsating headache, typically unilateral, lasting 4 to 72 hours, and often accompanied by nausea, vomiting, and sensitivity to light and sound (photophobia and phonophobia).

Approximately one third of people with migraine experience aura, which consists of transient visual, sensory, or speech disturbances that precede the headache.

Migraine attacks can be highly debilitating, and chronic migraine (defined as 15 or more headache days per month, of which at least 8 are migrainous) is a leading cause of disability worldwide.

Migraine prophylaxis is recommended for patients who experience frequent or disabling attacks.

NICE Guideline CG150 (Headaches in over 12s) recommends topiramate or propranolol as first-line options for migraine prevention in adults.

Topiramate is particularly useful in patients who wish to avoid weight gain associated with alternative preventive agents such as amitriptyline or pizotifen.

How Topamax works: mechanism of action

Topiramate is a sulfamate-substituted monosaccharide structurally distinct from all other anti-epileptic drugs. Its broad spectrum of anti-seizure activity is attributed to multiple mechanisms of action that work in concert to reduce neuronal hyperexcitability.

First, topiramate blocks voltage-gated sodium channels in a state-dependent manner.

This means it preferentially inhibits rapidly firing neurons (as occurs during a seizure) while having minimal effect on normal neuronal activity.

This reduces the sustained repetitive firing that characterises seizure propagation.

Second, topiramate enhances the inhibitory effects of GABA by potentiating GABA-A receptor-mediated chloride ion influx. This increases inhibitory neurotransmission, helping to dampen neuronal excitability. The site of action on the GABA-A receptor is distinct from the benzodiazepine binding site.

Third, topiramate antagonises glutamate activity at AMPA and kainate receptors, reducing excitatory neurotransmission. Glutamate is the principal excitatory neurotransmitter in the brain, and its overactivation is implicated in seizure generation and propagation.

Fourth, topiramate inhibits certain isoenzymes of carbonic anhydrase (types II and IV).

While this contributes to some of its side effects (paraesthesia, metabolic acidosis, kidney stones), it is not considered a primary anti-epileptic mechanism.

However, carbonic anhydrase inhibition may contribute to the drug's effects in certain seizure types.

Fifth, topiramate modulates voltage-gated calcium channels, further contributing to its effects on neuronal excitability.

In migraine prevention, the precise mechanism is not fully understood, but is thought to involve modulation of trigeminovascular signalling pathways, inhibition of cortical spreading depression (the neurophysiological correlate of migraine aura), and reduction of neuronal hyperexcitability in cortical and subcortical structures involved in migraine pathogenesis.

Clinical evidence and national guidelines

Epilepsy

Topiramate has been extensively studied in randomised controlled trials for both focal and generalised epilepsy.

As adjunctive therapy in drug-resistant focal epilepsy, pivotal trials demonstrated a median 40 to 50% reduction in seizure frequency compared with placebo.

The SANAD trial (Standard and New Antiepileptic Drugs), a large UK-based pragmatic trial, compared topiramate with other first-line AEDs and found it to be a suitable option for both focal and generalised epilepsy, although it was not always the best-tolerated option.

NICE NG217 lists topiramate as a recommended option for both focal and generalised tonic-clonic seizures, and specifically for Lennox-Gastaut syndrome.

Migraine prophylaxis

Multiple randomised controlled trials have demonstrated that topiramate 100 mg per day reduces migraine frequency by approximately 50% compared with placebo.

The MIGR-001, MIGR-002, and MIGR-003 trials showed that topiramate 100 mg per day was significantly superior to placebo in reducing monthly migraine days, with a responder rate (50% or greater reduction) of approximately 50%.

NICE CG150 recommends topiramate as a first-line option for migraine prophylaxis in adults, alongside propranolol.

The choice between the two is guided by patient preference, comorbidities, and side effect profile.

Dosage and administration

Topiramate is available as tablets (25 mg, 50 mg, 100 mg, 200 mg) and sprinkle capsules (15 mg, 25 mg, 50 mg).

Sprinkle capsules can be swallowed whole or opened and sprinkled onto a small amount of soft food (such as yoghurt or apple sauce) for patients who have difficulty swallowing tablets.

The food should be swallowed immediately without chewing.

Titration principles

Slow titration is essential.

Starting at a low dose and increasing gradually over several weeks reduces the incidence and severity of side effects, particularly cognitive impairment, paraesthesia, and mood disturbance.

The starting dose for most indications is 25 mg once daily in the evening, with increments of 25 to 50 mg at weekly or fortnightly intervals until the target dose is reached.

Epilepsy dosing

For monotherapy in adults, the usual target dose is 100 to 200 mg per day in two divided doses, with a maximum of 500 mg per day.

For adjunctive therapy, the usual effective dose range is 200 to 400 mg per day. Children receive weight-based dosing as directed by a paediatric neurologist.

Sprinkle capsules are preferred for young children.

Migraine prophylaxis dosing

The recommended dose for migraine prevention in adults is 100 mg per day (50 mg twice daily).

Titration begins at 25 mg in the evening for the first week, increasing by 25 mg per week until the target dose is reached.

Some patients respond to 50 mg per day. Doses above 100 mg per day have not been shown to provide additional benefit in migraine prophylaxis trials.

Side effects of Topamax

Very common side effects

Paraesthesia (tingling or numbness in the hands, feet, and face) is reported by up to 50% of patients and is the most common reason for early discontinuation.

It is caused by carbonic anhydrase inhibition and is usually dose-dependent. Weight loss from reduced appetite is common and may be significant in some patients.

Fatigue, dizziness, and somnolence are frequently reported, particularly during the titration phase.

Cognitive effects

Cognitive impairment is one of the most clinically significant side effects of topiramate. Patients commonly report difficulty with word-finding, reduced verbal fluency, impaired concentration, and slowed thinking.

These effects can affect academic performance, workplace productivity, and social interactions. They are more pronounced at higher doses and with rapid dose escalation.

In the SANAD trial, cognitive side effects were the most common reason for topiramate discontinuation. Slow titration and using the lowest effective dose help minimise cognitive effects.

Psychiatric effects

Depression, anxiety, irritability, mood swings, and behavioural changes have been reported.

The MHRA has issued a safety reminder that anti-epileptic drugs as a class are associated with a small increased risk of suicidal thoughts and behaviour.

Patients and their families should be counselled about this risk and advised to seek medical attention promptly if they notice any deterioration in mood or the emergence of suicidal thoughts.

Metabolic effects

Metabolic acidosis (low serum bicarbonate) occurs due to carbonic anhydrase inhibition. It is usually mild and asymptomatic but may cause hyperventilation, fatigue, and anorexia if significant.

Periodic monitoring of serum bicarbonate is recommended. Kidney stones (nephrolithiasis) occur in 1 to 2% of patients; adequate hydration is protective.

Ocular effects

Acute myopia with secondary angle-closure glaucoma is a rare idiosyncratic reaction, typically occurring within the first month of treatment.

Symptoms include sudden decrease in visual acuity and eye pain. It requires immediate discontinuation of topiramate and urgent ophthalmological assessment.

Unlike primary angle-closure glaucoma, this is caused by ciliary body swelling and forward displacement of the lens and iris, and is treated by stopping the drug rather than with peripheral iridotomy.

Thermoregulatory effects

Oligohydrosis (decreased sweating) and associated hyperthermia have been reported, predominantly in children. Parents and carers should monitor for signs of overheating, particularly during hot weather or vigorous physical activity, and ensure adequate fluid intake.

The MHRA Pregnancy Prevention Programme

Topiramate is classified as a teratogen.

Data from pregnancy registries and epidemiological studies have shown that exposure to topiramate during the first trimester of pregnancy is associated with a 2 to 3 fold increased risk of major congenital malformations, particularly orofacial clefts (cleft lip and/or cleft palate).

Topiramate exposure during pregnancy is also associated with fetal growth restriction, resulting in babies born small for gestational age.

Neurodevelopmental effects have also been investigated, although the evidence is less clear than for valproate.

In response to these risks, the MHRA introduced a Pregnancy Prevention Programme for topiramate in 2024, mirroring the existing programme for valproate.

Under this programme, topiramate must not be initiated in women and girls of childbearing potential unless the prescriber and patient have completed and signed an annual risk acknowledgement form, the patient has been counselled about the risks, a pregnancy test is negative, and highly effective contraception is in place.

Women using topiramate for migraine should be switched to an alternative preventive agent before attempting conception.

Women with epilepsy who plan pregnancy should discuss their treatment with a specialist, as stopping topiramate abruptly carries seizure risks.

Warnings and precautions

Gradual withdrawal

Topiramate must not be stopped abruptly in patients with epilepsy. Sudden discontinuation can precipitate rebound seizures, including tonic-clonic seizures and status epilepticus.

If discontinuation is planned, the dose should be tapered gradually over at least 2 to 8 weeks under medical supervision.

Hydration and kidney stones

Patients should maintain adequate fluid intake (at least 2 litres per day for adults) to reduce the risk of nephrolithiasis.

The risk is higher in patients with a personal or family history of kidney stones, those taking other carbonic anhydrase inhibitors (such as acetazolamide), and those on a ketogenic diet.

Drug interactions

Topiramate has clinically significant interactions with several medicines.

At doses above 200 mg per day, it induces CYP3A4 and can reduce plasma levels of ethinylestradiol, potentially reducing the efficacy of combined hormonal contraceptives.

Given the teratogenic risk, this interaction has critical safety implications. Topiramate may increase phenytoin levels by inhibiting CYP2C19. Carbamazepine and phenytoin reduce topiramate levels through enzyme induction.

Valproate and topiramate may have additive effects on hyperammonaemia and should be used together with caution. Review all medications with your prescriber before starting Topamax.

Driving and operating machinery

Topiramate may cause dizziness, drowsiness, and cognitive impairment, all of which can affect driving ability. The DVLA has specific regulations for people with epilepsy.

Group 1 (car and motorcycle) licence holders must be seizure-free for at least 12 months (or have an established pattern of seizures only during sleep) before driving.

Group 2 (lorry and bus) licence holders must be seizure-free and off all anti-epileptic medication for at least 10 years. Changes in medication require reassessment.

Notify the DVLA of your epilepsy diagnosis and any changes in treatment.

How to get a Topamax prescription in the UK

Topamax is a prescription-only medicine (POM) in the UK.

For epilepsy, it is typically initiated by a neurologist or epilepsy specialist and may be continued under shared care with the patient's GP.

For migraine prophylaxis, it may be initiated by a GP, headache specialist, or neurologist. All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients prescribed topiramate should ensure they attend regular follow-up appointments to monitor treatment efficacy, side effects, and, for women and girls of childbearing potential, compliance with the Pregnancy Prevention Programme.

Repeat prescriptions are available through GP surgeries and authorised online prescribers registered with the GPhC.

Living with epilepsy or migraine

Taking Topamax consistently as prescribed is essential for seizure control or migraine prevention.

In addition, patients with epilepsy should identify and avoid personal seizure triggers (such as sleep deprivation, alcohol, flashing lights, and stress), maintain a regular sleep pattern, and carry an epilepsy identification card or medical alert bracelet.

Patients with migraine should keep a headache diary to identify triggers, maintain a regular lifestyle with consistent sleep and mealtimes, and ensure adequate hydration.

Support organisations such as the Epilepsy Society, Epilepsy Action, and The Migraine Trust provide valuable resources, helplines, and peer support for people living with these conditions in the UK.

When to seek urgent medical advice

Call 999 or attend A&E if you experience a prolonged seizure lasting more than 5 minutes, repeated seizures without recovery between them (status epilepticus), a seizure in water, difficulty breathing during or after a seizure, or a serious injury during a seizure.

Seek urgent medical advice if you develop sudden visual disturbance or eye pain (possible acute glaucoma), severe mood changes or suicidal thoughts, signs of a severe allergic reaction (rash, swelling, difficulty breathing), or severe abdominal or flank pain (possible kidney stone).

Report any suspected adverse reactions to Topamax via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Topamax Tablets, Summary of Product Characteristics (EMC)
• Topiramate, British National Formulary (BNF)
• NICE NG217: Epilepsies in children, young people and adults
• NICE CG150: Headaches in over 12s
• MHRA: Topiramate Pregnancy Prevention Programme
• Topiramate, NHS
• MHRA Yellow Card Scheme